Elicio Therapeutics (ELTX) Change in Accured Expenses (2020 - 2026)
Elicio Therapeutics posted quarterly Change in Accured Expenses of -$602000.0 for Q1 2026, up 77.24% year-on-year from -$339652.3 in Q1 2025, and down 149.59% on a QoQ basis from $1.2 million in Q4 2025.
Elicio Therapeutics (ELTX) has 7 years of Change in Accured Expenses data on file, last reported at -$602000.0 in Q1 2026.
- For the quarter ending Q1 2026, Change in Accured Expenses rose 77.24% year-over-year to -$602000.0; the trailing twelve-month figure through Mar 2026 stood at $55000.0 (down 97.75% YoY), and the FY2025 full-year result was -$2.0 million, down 142.68% from the prior year.
- Change in Accured Expenses for Q1 2026 stood at -$602000.0, down from $1.2 million in the prior quarter.
- Across five years, Change in Accured Expenses topped out at $3.6 million in Q4 2024 and bottomed at -$2.6 million in Q1 2025.
- The 5-year median for Change in Accured Expenses is -$179000.0 (2022), against an average of $234058.8.
- The widest annual swing landed in 2024, when Change in Accured Expenses soared 1541.13%; it then plunged 512.27% in 2025.
- A 5-year view of Change in Accured Expenses shows it stood at -$235000.0 in 2022, then soared by 230.21% to $306000.0 in 2023, then soared by 1064.38% to $3.6 million in 2024, then plunged by 65.93% to $1.2 million in 2025, then sank by 149.59% to -$602000.0 in 2026.
- The last three Change in Accured Expenses figures came in at -$602000.0 (Q1 2026), $1.2 million (Q4 2025), and $107000.0 (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Accured Expenses (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 931,000.00 |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 70.50 Mn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 107.70 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | -176.03 Mn |
| 10 | Elicio Therapeutics | 217.63 Mn | 202.68 Mn | - | -602,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -602,000.00 |
| Mar 31, 2026 | -602,000.00 |
| Dec 31, 2025 | 1.21 Mn |
| Dec 31, 2025 | 1.21 Mn |
| Sep 30, 2025 | 107,000.00 |
| Sep 30, 2025 | 107,000.00 |
| Jun 30, 2025 | -664,000.00 |
| Jun 30, 2025 | -664,000.00 |
| Mar 31, 2025 | -2.65 Mn |
| Mar 31, 2025 | -2.65 Mn |
| Dec 31, 2024 | 3.56 Mn |
| Dec 31, 2024 | 3.56 Mn |
| Sep 30, 2024 | -508,000.00 |
| Sep 30, 2024 | -508,000.00 |
| Jun 30, 2024 | 2.04 Mn |
| Jun 30, 2024 | 2.04 Mn |
| Mar 31, 2024 | -432,000.00 |
| Mar 31, 2024 | -432,000.00 |
| Dec 31, 2023 | 306,000.00 |
| Dec 31, 2023 | 306,000.00 |
| Sep 30, 2023 | 2.16 Mn |
| Sep 30, 2023 | 2.16 Mn |
| Jun 30, 2023 | 124,000.00 |
| Jun 30, 2023 | 124,000.00 |
| Mar 31, 2023 | -375,000.00 |
| Mar 31, 2023 | -375,000.00 |
| Dec 31, 2022 | -235,000.00 |
| Dec 31, 2022 | -235,000.00 |
| Sep 30, 2022 | -179,000.00 |
| Sep 30, 2022 | -179,000.00 |
| Jun 30, 2022 | -1.91 Mn |
| Jun 30, 2022 | -1.91 Mn |
| Mar 31, 2022 | 2.02 Mn |
| Mar 31, 2022 | 2.02 Mn |
| Dec 31, 2021 | -2.17 Mn |
| Dec 31, 2021 | -2.17 Mn |
| Sep 30, 2021 | 837,000.00 |
| Sep 30, 2021 | 837,000.00 |
| Jun 30, 2021 | 2.11 Mn |
| Jun 30, 2021 | 2.11 Mn |
| Mar 31, 2021 | -769,000.00 |
| Mar 31, 2021 | -769,000.00 |
| Dec 31, 2020 | 1.76 Mn |
| Dec 31, 2020 | 1.76 Mn |
| Sep 30, 2020 | -751,000.00 |
| Sep 30, 2020 | -751,000.00 |
| Jun 30, 2020 | 878,000.00 |
| Jun 30, 2020 | 878,000.00 |
| Mar 31, 2020 | 1.82 Mn |
| Mar 31, 2020 | 1.82 Mn |